3D Pancreatic Cancer Models Have Been Developed
New 3D cell models could help researchers better match experimental pancreatic cancer treatments to individual patients.
Updated on Sept. 23, 2026 in Cancer
Live Poll
Should medical researchers prioritize using patient-derived human cell models to test new cancer treatments?
Genialis and Inventia Life Sciences have launched a partnership to build advanced, human-relevant 3D models for pancreatic ductal adenocarcinoma. By linking AI-driven patient profiles to these 3D systems, the collaboration aims to improve the precision of how potential cancer therapies are tested.
Why it matters
Current drug development for pancreatic cancer often struggles to translate lab results into clinical success, leaving patients with limited options. This collaboration seeks to bridge that gap by better mimicking the tumor microenvironment to identify which therapies are most likely to work for specific patients.
Researchers analyzed 644 pancreatic cancer patient tumors from the PanCAN SPARK cohort to map patient biology to 3D laboratory models. While preliminary, this analysis provides a foundation for connecting specific molecular states observed in patients to their corresponding lab-grown models.
The players
Genialis
A biotechnology company specializing in AI-driven patient insights to improve clinical trial success and drug development.
Inventia Life Sciences
A developer of advanced 3D cell-based platforms, including the RASTRUM system for high-throughput cancer research.
PanCAN
The Pancreatic Cancer Action Network, a non-profit organization dedicated to fighting pancreatic cancer through research and advocacy.
The details
The project integrates Genialis AI-powered patient insights with Inventia Life Sciences' RASTRUM platform, which creates 3D cell culture environments. Scientists map patient molecular profiles to tumor-fibroblast co-culture models on the RASTRUM platform to simulate the tumor microenvironment. The Genialis Supermodel then characterizes these 3D cultures, effectively connecting them to real-world clinical molecular states.
Timeline
September 23, 2026: Collaboration launch announced.
September 25, 2026: Researchers present initial results at the PanCAN Scientific Summit in San Diego.
Health Landscape
This effort represents a shift toward higher-fidelity disease models, moving away from traditional 2D cell cultures toward 3D environments that better represent human biology. It builds upon the foundation established by the PanCAN SPARK cohort to improve the accuracy of translational cancer research.
While this laboratory development does not immediately change current care, it signals progress in matching treatments to the specific biology of pancreatic tumors. Patients and their families may wish to discuss the role of clinical trials and molecular profiling with their oncology team.
The takeaway
Advancing 3D cell models is a critical step in creating personalized cancer therapies that better reflect human biology. Patients managing pancreatic cancer should speak with their oncologist about the availability of molecular tumor testing, which may help identify relevant clinical trials.
What happens next
The companies are scheduled to present their initial findings at the PanCAN Scientific Summit on September 25, 2026.
Further reading
For more information on the latest innovations in cancer research, explore the Cancer section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Should medical researchers prioritize using patient-derived human cell models to test new cancer treatments?
